2024 November
Ansgar Stratmann (W42 CEO) is invited speaker at the ‘Indo–German workshop on Aquatic Vaccination’ 27-29th November in Cochin (India).
The workshop is focused on challenges and new opportunities in vaccine development for Aquaculture. Ansgar Stratmann will present our technology to produce recombinant vaccines using Pichia pastoris as expression platform.


2024 April
W42 Industrial Biotechnology GmbH is a partner in the Delifeed research project, which is being funded by the Danish government for three years. 

New methods are being developed to enable efficient vaccination of fish in aquaculture via oral ingestion.
https://ecos.au.dk/forskningraadgivning/temasider/klimastresslab/projekter/delifeed-delivery-of-healthy-and-sustainable-live-feed-for-juvenile-fish

2023 December

As a result of an established collaboration with the research team from Prof. Dr. Khaled M. A. Aboshanab (Ain Shams University, Cairo) first results concerning the optimization of cephalosporin C production in Acremonium chrysogenum could be published.

https://doi.org/10.1186/s13568-023-01645-5

 

2023 October

Ansgar Stratmann (W42 CEO) is invited speaker at the ‘Fish vaccination workshop’ 18 & 19 of October in Porto.
The “grinnaqua initiative” – working for green innovation strategies for animal health management: towards sustainable aquaculture - is organising a workshop focused on fish vaccination. Ansgar Stratmann will present our activities to produce recombinant vaccines using Pichia p astoris as production host.

https://grinnaqua.eu
https://grinnaqua.eu/news/theoretical-practical-workshop-on-fish-vaccination


2023 May
W42 Industrial Biotechnology GmbH starts a cooperation with Chinese Pharma Company for production of Cephalosporin C based antibiotics.

Four high-producer Pichia strains were delivered to Zhejiang Anglikang Pharmaceutical Co., Ltd. in China. for the industrial scale production of technical enzymes. The enzymes will be used for the high-specific conversion of CPC to various antibiotics.

W42 Industrial Biotechnology GmbHis working together with EPITOGEN X for the development of AI based multivalent artificial vaccines.

In close cooperation with the Irish biotech company EPITOGEN X (epitogenx.com) we will develop artificial, multivalent vaccines to combat different pathogens affecting the global aquaculture industry. EPITOGEN X’s powerful and unique AI technology will identify the ‘most active’ epitopes in surface displayed proteins. The W42 expression platform will be used for the effective and profitable production of these 2nd generation vaccines on industrial scale.

2022 June

W42 Industrial Biotechnology GmbH has started in cooperation with Prof. C. Tafalla (INIA, CISC, Madrid) the development of a receptor-blocker for treatment of PKD disease in trout.
The soluble region of the receptor (BAFF-R) for binding of the cell-activating factor B (cytokine BAFF) as an antiparasitic agent for treatment of chronic inflammation in rainbow trout will be produced in Pichia pastoris.
Aim is to block the activity of BAFF with the aim of applying it as a therapeutic treatment during infections with proliferative kidney disease (PKD) in such a way that it can reduce the pathology associated with the infection (B-cell mediated), and therefore, reduce the mortality that it entails.

The project is financed by EU ERC fund, project 101100978.

 


2019 May

W42 Industrial Biotechnology GmbH is partner in a research cooperation aimed to develop a vaccine to combat sea-lice infection in salmon.
The consortium supported by a grant from the ‘Scottish Aquaculture Innovation Centre (SAIC)’ starts a research project for the development of an orally administered novel sea lice (Lepeophtheirus salmonis) vaccine targeting mucosal immunity.

SAIC project number SL_2019_03.

 


Projects for the global Aquaculture industry are carried out in close cooperation with
Aquatreck Animal Health S. L.  (www.aquatreck.com)